You are here: Industry Insights > Abecma

News List

Bristol-Myers Squibb’s Abecma gets approval in Japan for multiple myeloma ExpressPharma
January 24, 2022
The approval for Abecma is based on data obtained from the Phase II Study BB2121-MM-001 and the Phase I Study CRB-401.
BMS’ CAR T therapy Abecma moves closer toward EU approval pharmatimes
June 29, 2021
Bristol Myers Squibb’s (BMS) CAR T cell therapy Abecma has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of relapsed and ...
EMA human medicines committee meeting highlights, June 2021 europeanpharmaceuticalreview
June 28, 2021
Drugs recommended for approval by the European Medicines Agency’s human medicines committee included a gene therapy and two generics, among five others.
BMS to invest in new cell therapy manufacturing site in Europe pharmatimes
April 26, 2021
Bristol Myers Squibb (BMS) is planning to invest in a new cell therapy manufacturing site based in Leiden in the Netherlands.
Bristol Myers Squibb and bluebird bio get US FDA nod for Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple myeloma expresspharma
March 29, 2021
Abecma is a first-in-class BCMA-directed personalised immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma.